Moleculin Biotech, Inc.

MBRX

US60855D3098

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
4.77 ^USD	+2.80%		-3.25%	-62.95%

May. 15	Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)	CI
May. 13	Transcript : Moleculin Biotech, Inc., Q1 2024 Earnings Call, May 13, 2024

68,000 shares of Moleculin Biotech, Inc.'s Common Stock are subject to a Lock-Up Agreement Ending on 1-JAN-2017.

January 31, 2016

68,000 shares of Moleculin Biotech, Inc.'s Common Stock are subject to a Lock-Up Agreement Ending on 1-JAN-2017. These shares will be under lockup for 214 days starting from 1-JUN-2016 to 1-JAN-2017.

Latest news about Moleculin Biotech, Inc.

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)	May. 15	CI
Transcript : Moleculin Biotech, Inc., Q1 2024 Earnings Call, May 13, 2024	May. 13
Moleculin Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Transcript : Moleculin Biotech, Inc. - Special Call	May. 07
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data	May. 07	CI
Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman	May. 01	CI
Transcript : Moleculin Biotech, Inc. - Special Call	Apr. 24
Sector Update: Health Care Stocks Ease in Afternoon Trading	Apr. 18	MT
Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU	Apr. 18	MT
Top Premarket Decliners	Apr. 16	MT
Transcript : Moleculin Biotech, Inc. - Special Call	Mar. 28
Sector Update: Health Care Stocks Advance Late Afternoon	Mar. 27	MT
Sector Update: Health Care	Mar. 27	MT
Moleculin Biotech Shares Rise Following Patent Announcement	Mar. 27	MT
Maxim Adjusts Price Target on Moleculin Biotech to $20 From $45, Maintains Buy Rating	Mar. 26	MT
Transcript : Moleculin Biotech, Inc., 2023 Earnings Call, Mar 25, 2024	Mar. 25
Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial	Mar. 25	CI
Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
North American Morning Briefing : Markets on Hold as Fed Decision Nears	Mar. 20	DJ
Moleculin Biotech to Effect 1-For-15 Reverse Stock Split to Regain Compliance	Mar. 19	MT
Transcript : Moleculin Biotech, Inc. - Special Call	Feb. 28
Transcript : Moleculin Biotech, Inc. - Special Call	Feb. 14
Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3	Jan. 24	CI
Moleculin Biotech, Inc. announced that it expects to receive $9.01739 million in funding	Dec. 19	CI
Transcript : Moleculin Biotech, Inc. - Special Call	Dec. 17

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.77 USD

Average target price

35 USD

Spread / Average Target

+633.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MOLECULIN BIOTECH, INC.	-62.95%	10.63M
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B

Bio Therapeutic Drugs

Moleculin Biotech, Inc.

Equities

MBRX

US60855D3098

Biotechnology & Medical Research

68,000 shares of Moleculin Biotech, Inc.'s Common Stock are subject to a Lock-Up Agreement Ending on 1-JAN-2017.

Latest news about Moleculin Biotech, Inc.

Chart Moleculin Biotech, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs